Treatment of pulmonary arterial hypertension using therapeutically effective oral doses of 10-nitro-9(e)-octadec-9-enoic acid

Abstract

Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating diseases, including focal segmental glomerulosclerosis or pulmonary arterial hypertension. The compositions of such embodiments include activated fatty acids such as alkyl substituted fatty acids, keto fatty acids and nitro fatty acids. The methods of various embodiments include administering an effective amount of 10-nitro-9(E)-octadec-9-enoic acid to treat such diseases.

1 . A method of treating sickle cell disease in a subject in need thereof, comprising:
 a. administering to said subject a daily dose of 10-nitro-9(E)-octadec-9-enoic acid in an amount of at least 25 milligrams (mg).   
     
     
         2 . The method of  claim 1 , wherein said daily dose is administered orally. 
     
     
         3 . The method of  claim 1 , wherein said daily dose is at least 120 mg. 
     
     
         4 . The method of  claim 1 , wherein said daily dose is no more than 450 mg. 
     
     
         5 . The method of  claim 1 , wherein said daily dose is divided into two doses per day. 
     
     
         6 . The method of  claim 1 , wherein said two doses per day are of equal weight. 
     
     
         7 . A method of treating sickle cell disease in a subject in need thereof, comprising:
 a. administering to said subject at least 25 milligrams (mg) of 10-nitro-9(E)-octadec-9-enoic acid.   
     
     
         8 . The method of  claim 1 , wherein said 10-nitro-9(E)-octadec-9-enoic acid is administered orally. 
     
     
         9 . The method of  claim 1 , wherein at least 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, or 300 mg of said 10-nitro-9(E)-octadec-9-enoic acid is administered. 
     
     
         10 . The method of  claim 9 , wherein said 10-nitro-9(E)-octadec-9-enoic acid is administered once daily. 
     
     
         11 . The method of  claim 9 , wherein said 10-nitro-9(E)-octadec-9-enoic acid is administered twice daily. 
     
     
         12 . The method of  claim 9 , wherein said 10-nitro-9(E)-octadec-9-enoic acid is administered three times daily. 
     
     
         13 . The method of  claim 9 , wherein said 10-nitro-9(E)-octadec-9-enoic acid is administered four times daily.